{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Survey Questionnaire

  1. Which of the following statements do you think most related to Indian Diabetic Phenotype (Tick any two) *

  2. As diabetes is cardio risk equivalent in general do you believe diabetes increases risk of heart failure manifold (Tick any one)? *

  3. How do you compare risk of CKD as compared to heart failure in your diabetic Patient population (Tick any one)? *

  4. According to you how much is the importance of legacy effect / or Metabolic memory in managing T2DM *

  5. What % of Your diabetes patients have high PPHG *

  6. What are the causes of High PPHG in Indians? *

  7. What % of your patients do you manage with SU based therapy? *

  8. Newly detected Diabetes patient with high PPHG what options from below you prefer *

  9. How do you compare risk of CKD as compared to Heart failure in your diabetic patient population (tick any one) *

  10. Generally diabetes being a multifactorial disease do you believe targeting multiple pathophysiologies can offer better glycemic Control? *

  11. What is the rationale of choosing Fixed dose combination in T2DM? *

  12. What according to you are the merits of FDC in Diabetes treatment (Choose any 2) *

  13. In your 100 Diabetic patients what % of patients would you have on (Sum Total of response should be 100) *

    		14.
    %

    %

    %

    %
  14. Amongst the FDC of SGLT2i+DPP4i which of the following distinguishing parameters do you find most attractive (tick any one) *

  15. Among the newer oral antidiabetic, do you consider SGLT2 inhibitors and DPP4 inhibitors as equally Efficacious? *

  16. Rank the SGLT2 inhibitors in terms of glycemic control efficacy (from 1 to 4, 1 being the highest) *

    		17.

  17. Rank the DDP4 inhibitors in terms of glycemic control efficacy (from 1 to 2, 1 being the highest) *

    		18.

  18. On patients uncontrolled on metformin, which if the following class of drug would you like to initiate first? *

  19. In diabetes patient with established ASCVD or heart failure, which class of the drug will be preferred by you as a second line treatment? *

  20. In Low-risk diabetes patients (without HF/ ASCVD or CKD), when there is a need to reduce the chances of hypoglycemia, which of the following class of drug would you prefer as a second line treatment *

  21. Among elderly diabetic patients, which of the following class of drug would you prefer taking into consideration the safety aspects *

  22. According to you, initial usage of SUs would be replaced by which class of drug? *

  23. In your 100 diabetic patients, what % of patients, you would like to recommend below class of new OAD FDC? (Sum Total of response should be 100 %) *

    24. %

    %

    %
  24. In patients with high ASCVD risk with Type 2 Diabetes, in addition to comprehensive CV risk management which class of drug you will recommend (1 = low recommendation and 5 = high recommendation) *

  25. In the patients < 55 Years of age with two or more additional risk factors (obesity, hypertension, smoking, dyslipidemia, or albuminuria) with T2DM management which class of drug you will recommend (1 = low recommendation and 5 = high recommendation) *

  26. In patients with CHF (documented HFrEF or HFpEF) with T2DM which SGLT2 you always prefer the most? *

  27. Which class of drug you will prescribe to CKD patients with T2DM? *

  28. For achievement of glycemic and weight management goals in T2DM patients which from the following you always prefer (you can select multiple options) *

  29. For achievement and maintenance of weight management Goals what is your approach in T2DM patients (you can select multiple options) *

  30. When choosing glucose lowering therapies in T2DM patients please choose your approach from the following classes of drugs with the viewpoint of efficacy for weight loss *